Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex.
Antisense oligonucleotides, and particularly those with phosphorothioate backbones, have emerged as potential gene specific therapeutic agents and are currently undergoing evaluation in clinical trials for a variety of diseases. In the area of HIV-1 therapeutics, targeting of oligonucleotides to infected cells, such as macrophages, would be highly desirable. The present study was designed to prepare and characterize oligonucleotide-loaded nanoparticles for this purpose. Due to their hydrophilic characteristics, oligonucleotides are difficult to entrap in polymeric particles. Here, the oligonucleotides were first complexed with cetyltrimethylammonium bromide. The oligonucleotide-loaded nanoparticles were prepared by the emulsification-diffusion method and subsequently purified. In comparison with previous studies, a high oligonucleotide-loading was achieved; 2.5, 5 and 10% oligonucleotide loading were assessed. If the initial oligonucleotide content was 4%, this method produced a final oligonucleotide loading of 1.9% with an entrapment efficiency of 47%. The integrity of the oligonucleotide and of the polymer, in the final freeze-dried product, was retained.
Berton
M
M
School of Pharmacy, University of Geneva, quai E.-Ansermet CH-1211, Geneva, Switzerland.
Allémann
E
E
Stein
C A
CA
Gurny
R
R
D000077286:Cetrimonium; D002593:Cetrimonium Compounds / Q000737:chemistry*; D004058:Diffusion; D016503:Drug Delivery Systems / Q000379:methods*; D004355:Drug Stability; D004655:Emulsions; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D016376:Oligonucleotides, Antisense / Q000737:chemistry* / Q000302:isolation & purification; D010316:Particle Size; D010757:Phosphorous Acids / Q000737:chemistry*; D011108:Polymers / Q000737:chemistry*; D012995:Solubility
D002593:Cetrimonium Compounds; D004655:Emulsions; D016376:Oligonucleotides, Antisense; D010757:Phosphorous Acids; D011108:Polymers; D000077286:Cetrimonium